Quoin Pharmaceuticals Ltd. has announced a new sales agreement with Leerink Partners LLC, allowing the company to sell American Depositary Shares (ADSs) as part of its strategy to raise capital. This agreement, filed on November 4, 2026, is significant for Quoin as it seeks to leverage market opportunities for funding through at-the-market offerings.

The sales agreement permits Quoin to sell ADSs, each representing 35 of the company’s ordinary shares, through Leerink Partners acting as the agent. The sales will be conducted in accordance with Rule 415(a)(4) under the Securities Act of 1933, which defines at-the-market offerings. This approach allows Quoin to sell shares directly on Nasdaq or other trading markets, providing flexibility in capital raising.

According to the filing, Leerink Partners will use commercially reasonable efforts to place all ADSs requested by Quoin, with the firm entitled to a 3.0% commission on the gross sale proceeds. Both parties have the right to suspend the offering or terminate the agreement at any time with proper notice.

Quoin Pharmaceuticals, based in Ashburn, Virginia, operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company has been active in the market, filing multiple forms with the SEC recently, including a registration statement on Form S-3, which was declared effective concurrently with this sales agreement.

The new agreement is expected to enhance Quoin's financial flexibility, allowing the company to respond to market conditions and investor interest effectively. This move aligns with trends in the pharmaceutical industry where companies are increasingly utilizing at-the-market offerings to raise capital efficiently.

As part of the sales agreement, Quoin has committed to providing indemnification to Leerink Partners against certain liabilities, which is a customary practice in such agreements. The company also disclosed that Leerink Partners has previously provided investment banking services to them, indicating an ongoing relationship.

Looking ahead, Quoin Pharmaceuticals will continue to monitor market conditions and investor appetite for its ADSs. The company has filed a prospectus supplement related to the ADSs, which will provide additional details to potential investors.

This development marks a strategic step for Quoin Pharmaceuticals as it seeks to bolster its capital base and expand its operations in the competitive pharmaceutical landscape.